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Efﬁcacy  of afoxolaner,  a  novel  isoxazoline  insecticide/acaricide,  against  Ixodes  scapularis
was  evaluated  in  a laboratory  study.  One  day  prior  to treatment,  beagle  dogs  (n =  16)  were
infested  with  50  unfed  wild  adult  ticks.  Repeat  infestations  were  performed  weekly  for
four additional  weeks.  The  number  of  live  ticks  remaining  on  each  dog  was  determinedicks
ral
48  h after  treatment  and  after  each  subsequent  infestation.  A  single  oral  treatment  with
a dose  approaching  the  minimum  effective  dose  of  afoxolaner  (2.5  mg/kg)  eliminated  the
pre-existing infestations  of I. scapularis  ticks  and  controlled  weekly  re-infestations,  with
efﬁcacy between  98%  and  100%  recorded  until  Day 23  and  94%  at Day  30.
©  2014  The  Authors.  Published  by  Elsevier  B.V.  This  is an  open  access  article  under  the  CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
Tick control is an important concern for public health
fﬁcials, pet owners, and veterinarians (Dantas-Torres
t al., 2012; Mencke, 2013). Ixodes scapularis ticks have
ecome an increasingly important concern for public and
eterinary health (Dantas-Torres et al., 2012; Otranto and
all, 2008). These ticks can carry a variety of infec-
ious agents, some of which are zoonotic and may  be
ife-threatening, including the organisms that cause Lyme
orreliosis, babesiosis, and ehrlichiosis in both dogs and
umans (Chomel, 2011; Colwell et al., 2011; Varde et al.,
998). The geographic distribution of I. scapularis ticks is
lso expanding, in part through infestation of migratory
irds (Hamer et al., 2012; Ogden et al., 2008). Several tick
pecies, including I. scapularis,  are also capable of trans-
itting a salivary neurotoxin that can block acetylcholineransmission and lead to ﬂaccid paralysis in dogs and
umans (Blagburn and Dryden, 2009; Vedanarayanan et al.,
004).
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icenses/by-nc-nd/3.0/).There are several strategies available to control tick
infestations, including avoidance of infested environments,
particularly during periods when ticks are active (Otranto
et al., 2009; Blagburn and Dryden, 2009). Regular admin-
istration of an acaricide is also important since owners
may  not be aware of what tick species are common in
their area and avoiding infested environments may  be
difﬁcult. There are many topically applied acaricidal prod-
ucts currently available as spot-on formulations or collars.
These compounds, which can be highly efﬁcacious against
some tick species, include amitraz, ﬁpronil and pyrethroids
(permethrin, deltamethrin, and ﬂumethrin) (Beugnet and
Franc, 2012). Despite their reported effectiveness, there
are some concerns about the use of topical products due
to differences in dogs’ hair coats that may  affect efﬁcacy,
adverse effects of shampooing or bathing after application
on efﬁcacy, possible toxic effects of products on non-target
species, or cosmetic concerns (Dryden and Payne, 2004;
Malik et al., 2010). Therefore, an orally administered acari-
cide may  be preferable for many pet owners.Afoxolaner is a novel insecticide–acaricide adminis-
tered orally in a chewable formulation (Nexgard®, Merial)
designed to treat and control ﬂeas and ticks on dogs. This
paper describes an experimental study that was  performed
ss article under the CC BY-NC-ND license (http://creativecommons.org/
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Table 1
Geometric mean (range) live Ixodes scapularis tick counts on control
dogs 48 h after treatment (Day −1 infestation) or after subsequent re-
infestations and percent efﬁcacy on treated dogs.
Day of
infestation
Day of tick
count
Geometric mean live
ticks (range)a
% Efﬁcacy
−1 2 21.1 (15–29) 98.4
7 9 14.1 (4–25) 100
14 16 20.9 (15–32) 99.1
21 23 20.9 (15–29) 99.6
28 30 14.2 (7–29) 94.2
a There was a signiﬁcant difference (p < 0.001) in tick counts between224 E.B. Mitchell et al. / Veterina
to demonstrate the efﬁcacy of afoxolaner against I. scapu-
laris, a North American tick species that commonly infests
dogs.
2. Materials and methods
2.1. Experimental design
A study was conducted to demonstrate the efﬁcacy of
afoxolaner against I. scapularis.  The study was performed
in the United States and was designed in accordance with
standard methods for evaluating the efﬁcacy of parasiti-
cides for the treatment, prevention and control of tick
infestations (Marchiondo et al., 2013). It complied with
Merial and local Institutional Animal Care and Use Com-
mittee requirements and international laws and ethics
standards. Dogs were managed with regard to US Animal
Welfare Regulations, 2008, 9 CFR (USDA, 2008).
2.2. Animals
The study involved 16 purpose bred beagles, which were
individually identiﬁed by unique ear tattoos. Eight male
and eight female dogs aged 6–8 months and weighing
5.2–8.7 kg were included. Dogs were in good health and
had not been treated with ectoparasiticides for at least 3
months prior to the start of the study. Tick infestations
and subsequent counts were performed prior to treatment
and conﬁrmed that the dogs were capable of maintaining
adequate tick infestations. Dogs were housed individu-
ally. Health observations were conducted daily throughout
the study. In addition, health observations were conducted
every hour for 4 h following treatment with afoxolaner on
Day 0.
2.3. Study design
The study followed a controlled, randomized block
design, including 16 dogs (8 per group). Six days prior
to treatment dogs were infested with 50 adult I. scapu-
laris ticks, which were removed and counted 48 h later.
The pre-treatment tick counts were used to allocate dogs
to either the control or afoxolaner-treated group. Dogs in
Group 1 were untreated controls. Dogs in Group 2 were
treated once orally on Day 0 with the appropriate com-
bination of soft chewables containing afoxolaner. Chews
weighing 0.5 g and containing 11.3 mg  of afoxolaner were
used. As the chewables are not designed to be divided, the
dosing was administered as closely as possible to the min-
imum effective dose of 2.5 mg/kg using whole chews. The
actual dosage administered to the dogs ranged from 2.7 to
3.7 mg/kg of body weight.
Dogs were infested with 50 adult ticks on the day prior
to treatment (Day −1) and on Days 7, 14, 21, and 28.
Forty-eight hours after treatment and 48 h after each of the
subsequent re-infestations, ticks were removed and live
ticks counted. These counts were conducted during a pro-
cess that involved methodical examination of all body areas
using ﬁnger tips and/or a coarse tooth comb to sort through
the hair and locate all ticks on the animal, as described by
Marchiondo et al. (2013). The I. scapularis ticks used in thisafoxolaner-treated and control dogs at all time points up to Day 30.
study were unfed adult ticks, approximately 50% male and
50% female, collected from the wild in the USA. Personnel
responsible for collection of animal health and efﬁcacy data
were blinded to the treatment groups.
2.4. Data analysis
Total counts of live ticks were transformed to the natural
logarithm of (count + 1) for calculation of geometric means
by treatment group at each time point. Percent reduction
from the control group mean was calculated for the treated
group at each post-treatment time point using the formula
[(C − T)/C] × 100, where C is the geometric mean for the
control group and T is the geometric mean for the treated
group. The log counts of the treated group were compared
to the log counts of the untreated control group using an
F-test adjusted for the allocation blocks used to randomize
the animals to the treatment groups. The mixed procedure
in SAS® version 9.1.3 was  used for the analysis, with treat-
ment group listed as a ﬁxed effect and the allocation blocks
listed as a random effect. The comparisons were performed
using a two-sided test with a 5% signiﬁcance level.
3. Results
No vomiting was reported in treated dogs during the
study based on observations every hour for 4 h after dosage
and daily observations thereafter. No treatment-related
health problems were observed throughout the study.
The number of ticks counted on untreated control dogs
exceeded 20% of the challenge (50 ticks) at all time points,
as recommended by Marchiondo et al. (2013), to allow a
robust comparison with the treated dogs (Table 1).
Efﬁcacy results against I. scapularis are presented in
Table 1. Dogs were infested one day prior to treatment
and afoxolaner provided 98.4% curative efﬁcacy against I.
scapularis at the 48 h count (Table 1). Dogs were re-infested
with 50 adult ticks on a weekly basis through Day 28, and
the efﬁcacy 48 h after each re-infestation was 100%, 99.1%,
99.6%, and 94.2% at Days 9, 16, 23, and 30, respectively
(Table 1). There was a signiﬁcant difference (p < 0.001)
between treated and control dogs for counts of ticks at all
time points through Day 30 (Table 1).
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. Discussion
In this study a single oral dose of afoxolaner at the
inimum effective dose was highly effective in eliminat-
ng existing infestations of I. scapularis,  with efﬁcacy of
8.4% within 2 days following treatment. It also provided
xtended efﬁcacy following re-infestation with ticks, with
99% up to 23 days after treatment and >94% efﬁcacy one
onth after treatment.
Nexgard® is the ﬁrst orally administered product
hat kills I. scapularis ticks. Afoxolaner acts systemically
nd requires ticks to feed, however, the study reported
ere demonstrated persistently high efﬁcacy assessed at
8 h. Such efﬁcacy is similar to other commercialized
roducts that are applied topically. For example, one
tudy assessed the efﬁcacy of topical products containing
pronil + (S)-methoprene and imidacloprid + permethrin
gainst I. scapularis ticks; results were 98.4% and 96.5%,
espectively, 48 h following infestation on Day 30 (Dryden
t al., 2006). Concern has been expressed that systemi-
ally acting products would take longer to kill ticks than
opically applied products. For instance, Marchiondo et al.
2013) suggest that tick attachment of 72 h or longer may
e acceptable for products with a systemic mode of action.
owever, the results from the current study demonstrate
hat afoxolaner, administered orally in Nexgard®, provides
90% efﬁcacy against I. scapularis within 48 h of infestation
or at least one month.
It is important that products used to control tick infes-
ations be effective at a level greater than 90%, in order
o provide relief from blood loss and irritation associated
ith tick bites (Marchiondo et al., 2013; Dryden and Payne,
004).
The oral route of administration may  be preferred
y some owners over topical parasiticide products. For
nstance, the efﬁcacy of some topical products may  be
ffected by bathing or swimming, or there may  be a period
f time in which the application site should be avoided
y pet owners or other household animals (Dryden and
ayne, 2004). Also, the density and length of the dog’s hair
oat does not affect the application of an oral product as
t can with a topical product. The chewable formulation of
exgard® is also advantageous in that it is palatable and
oluntarily consumed by dogs, making it easy and conve-
ient for owners to administer.
. Conclusions
This study demonstrated the efﬁcacy of a single oral
ose of afoxolaner against I. scapularis.  Existing tick infes-
ations were rapidly cleared and there was a residual
rotection against ticks for at least a month.
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